Enhanced topical delivery of fish scale collagen employing negatively surface-modified nanoliposome

Seo, Jeong-Sun; Kim, Min-Ju; Jeon, Sang-Ok; Oh, Dong-Ho; Yoon, Kyu-Hyung; Choi, Young Wook; Bashyal, Santosh; Lee, Sang Kil

doi:10.1007/s40005-017-0303-2

Cited by 22 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… [25] , [26] . Cationic immunoliposome could serve as a good delivery system owing to numerous advantages such as target-specific delivery, biocompatibility and safety [27] , [28] , [29] . To formulate a lipoplex with the mi/siRNA complex, cationic liposomes were prepared with DOPE:DC-chol at 1:0.5, 1:1 and 1:1.5 molar ratios.…”

Section: Resultsmentioning

confidence: 99%

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells

Shin

Kim

2020

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Recently, breast cancer stem cells (BCSCs) have rapidly emerged as a novel target for the therapy of breast cancer as they play critical roles in tumor growth, maintenance, metastasis, and recurrence. Let-7 miRNA is known to be downregulated in a variety of cancers, especially BCSCs, whereas CDK4 being overexpressed in human epidermal growth factor receptor 2 (HER-2) overexpressing tumor cells. In this study, let-7 miRNA and CDK4-specific siRNA were chosen as therapeutic agents and co-encapsulated in Herceptin-conjugated cationic liposomes for breast cancer therapy. Particle size, zeta potential, and encapsulation efficacy of mi/siRNA-loaded PEGylated liposome conjugated with Herceptin (Her-PEG-Lipo-mi/siRNA) were 176 nm, 28.1 mV, and 99.7% ± 0.1%, respectively. Enhanced cellular uptake (86%) was observed by fluorescence microscopy when SK-BR-3 cells were treated with Her-PEG-Lipo-mi/siRNA. Also, the increased amount of let-7a mRNA and decreased amount of cellular CDK4 mRNA were observed by qRT-PCR when SK-BR-3 cells were treated with Her-PEG-Lipo-mi/siRNA, which was even more so when SK-BR-3 stem cells were used (197 vs 768 times increase for let-7a, 62% vs 68% decrease for CDK4). Growth inhibition (65%) and migration arrest (0.5%) of the cells were achieved by the treatment of the cells with Her-PEG-Lipo-mi/siRNA, but not with mi/siRNA complex or other formulations. In conclusion, an efficient liposomal delivery system for the combination of miRNA and siRNA to target the BCSCs was developed and could be used as an efficacious therapeutic modality for breast cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells

Shin

Kim

2020

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…Liposomes are an efficient drug delivery system composed of double-layered phospholipids [10,30,31]. Liposomes are biodegradable, biocompatible, and amenable to the incorporation of both hydrophilic and lipophilic drugs [32,33].…”

Section: Lipid-based Formulationsmentioning

confidence: 99%

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

et al. 2020

View full text Add to dashboard Cite

Colon targeted drug delivery systems have gained a great deal of attention as potential carriers for the local treatment of colonic diseases with reduced systemic side effects and also for the enhanced oral delivery of various therapeutics vulnerable to acidic and enzymatic degradation in the upper gastrointestinal tract. In recent years, the global pharmaceutical market for biologics has grown, and increasing demand for a more patient-friendly drug administration system highlights the importance of colonic drug delivery as a noninvasive delivery approach for macromolecules. Colon-targeted drug delivery systems for macromolecules can provide therapeutic benefits including better patient compliance (because they are pain-free and can be self-administered) and lower costs. Therefore, to achieve more efficient colonic drug delivery for local or systemic drug effects, various strategies have been explored including pH-dependent systems, enzyme-triggered systems, receptor-mediated systems, and magnetically-driven systems. In this review, recent advancements in various approaches for designing colon targeted drug delivery systems and their pharmaceutical applications are covered with a particular emphasis on formulation technologies.

show abstract

“…Among nanocarriers, liposomes are promising delivery vectors since they are biocompatible, biodegradable, and capable of encapsulating both hydrophilic and hydrophobic drugs [7,8]. In addition, liposomes can undergo various surface modifications to control the site of drug release and uptake as well as physiological stability [9][10][11]. For example, to enhance colonic drug delivery, the liposomal surface can be coated with mucoadhesive or pH-sensitive polymers to release the drug preferably at the distal part of the intestine and also lengthen the retention time in the colon [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization

et al. 2020

View full text Add to dashboard Cite

This study aimed to develop a new colon-targeted drug delivery system via the preparation of ternary nanocomposite carriers based on organic polymer, aminoclay and lipid vesicles. Budesonide (Bud), an anti-inflammatory drug was chosen as a model drug and encapsulated into three different formulations: liposome (Bud-Lip), aminoclay-coated liposome (AC-Bud-Lip), and Eudragit ® S100-aminoclay double coated liposome (EAC-Bud-Lip). The formation of the aminoclay-lipid vesicle nanocomposite was confirmed by energy dispersive X-ray spectrum, transmission electron microscopy, and Fourier-transform infrared spectroscopy. All formulations were produced with a high encapsulation efficiency in a narrow size distribution. Drug release from EAC-Bud-Lip was approximately 10% for 2-h incubation at pH 1.2, implying the minimal drug release in acidic gastric condition. At pH 7.4, EAC-Bud-Lip underwent significant size reduction and exhibited drug release profiles similar to that from AC-Bud-Lip, implying the pH-dependent removal of the outer coating layer. Compared to free Bud solution, EAC-Bud-Lip achieved a higher drug uptake in Caco-2 cells and exhibited a stronger inhibition of TNF-α and IL-6 secretion in LPS-stimulated Raw264.7 cells. Furthermore, a bio-distribution study in mice demonstrated that Eudragit ® S100-aminoclay dual coating led to a higher colonic distribution with a longer residence time, which correlated well with the delayed systemic drug exposure in rats. Taken together, the present study suggests that the ternary nanocomposite carrier consisting of Eudragit ® S100, aminoclay, and lipid vesicle might be useful as an effective colon-targeted drug delivery system.

show abstract

Enhanced topical delivery of fish scale collagen employing negatively surface-modified nanoliposome

Cited by 22 publications

References 34 publications

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells

Let-7 miRNA and CDK4 siRNA co-encapsulated in Herceptin-conjugated liposome for breast cancer stem cells

Strategic Approaches for Colon Targeted Drug Delivery: An Overview of Recent Advancements

Ternary nanocomposite carriers based on organic clay-lipid vesicles as an effective colon-targeted drug delivery system: preparation and in vitro/in vivo characterization

Contact Info

Product

Resources

About